Cahill, Kate and Ussher, Michael H (2011) Cannabinoid type 1 receptor antagonists for smoking cessation. Cochrane Database of Systematic Reviews, (3), Art. No.: CD005353. DOI: 10.1002/14651858.CD005353.pub4..
External website: http://onlinelibrary.wiley.com/doi/10.1002/1465185...
Objectives:
• To determine whether selective CB1 receptor antagonists (currently rimonabant and taranabant) increase the numbers of people stopping smoking
• To assess their effects on weight change in successful quitters and in those who try to quit but fail.
Conclusions: From the trial reports available, rimonabant 20 mg may increase the chances of quitting approximately 1½-fold. The evidence for rimonabant in maintaining abstinence is inconclusive. Rimonabant 20 mg may moderate weight gain in the long term. Taranabant 2-8 mg may moderate weight gain, at least in the short term. In 2008, development of both rimonabant and taranabant was discontinued by the manufacturers.
E Concepts in biomedical areas > Nervous system physiology (brain, neural)
HJ Treatment or recovery method > Substance disorder treatment method > Substance disorder drug therapy (pharmacological treatment)
HJ Treatment or recovery method > Substance disorder treatment method > Cessation of substance use
VA Geographic area > International
Repository Staff Only: item control page